| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Allergan is a global specialty pharmaceutical company that develops and
commercializes products for the eye care, neuromodulator, skin care and other
specialty markets. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
With headquarters in Irvine, California, Allergan is a global specialty
pharmaceutical company that develops and commercializes products for the eye
care, neuromodulator, skin care and other specialty markets. In addition to
its discovery-to-development research programmes, Allergan, which was founded
in 1948, has global marketing and sales capabilities in over 100 countries. It
has a workforce of over 5,000 people and invests approximately US$390 million
per year in research and development.
Over recent years, Allergan has made a number of changes aimed at simplifying
the company's business model, enabling Allergan to take advantage of its
position as a relatively modest player in the pharmaceutical industry.
Allergan has chosen a distinct company strategy, focusing strongly on the
development and marketing of speciality products. This tactic seems to have
proved effective, with Allergan achieving a market leader position in the area
of neuromodulators with Botox, and in ophthalmology with its range of eye care
therapeutics. The recent acquisition of Inamed should ensure Allergan
maintains a strong presence in the field of medical aesthetics as well.
Historically, Allergan's expertise has been in the development of topical
pharmaceuticals for ophthalmology and dermatology. In recent years, the
company has begun building new competencies in the design and clinical
investigation of oral drugs. Allergan is aiming to build a balanced pipeline
of innovative new chemical entities, line extensions and product enhancements
that deliver a consistent flow of new products to drive corporate growth.
Allergan is focusing its R&D efforts on new therapeutic areas, including
gastroenterology and genitourinary diseases. Allergan is also focusing on the
more severe end of the spectrum of the dermatological diseases of acne and
psoriasis.
TABLE OF CONTENTS
- Principal Operating Results
- Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Geographical Area/Business Area
- R&D Expenditure
- Divisional Performance
- Geographic Performance
- Sales By Origin
- Long-Lived Assets By Geographical Area
- Company Strategy
- Acquisitions and Divestitures
- Acquisitions
- Divestitures
- Key Agreements
- Discontinued Agreements
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy/Pipeline Overview
- Sales Forecasts
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Neurosciences - Products
- Botox/Dysport
- Sales
- Key Markets/Indications
- Botox Cosmetic
- Lawsuits
- Further Development
- Sales Forecast
- Clinical Trial Results - Migraine Headache
- Clinical Trial Results - Overactive Bladder
- Neurosciences - R&D
- Neurosciences - Summary
- Growth Potential
- Limiting Factors
- Ophthalmology - Products
- Major Launched Products
- Alphagan/Alphagan P
- Sales
- Key Markets/Indications
- Further Development
- Patents/Licensees
- Competitor Products
- Patents/Lawsuits/Generic Competition
- Sales Forecast
- Lumigan
- Mechanism of Action
- Sales
- Key Markets/Indications
- Further Development
- Patents
- Competitor Products
- Sales Forecast
- Clinical Trial Results
- Restasis
- Sales
- Key Markets/Indications
- Licensees
- Sales Forecast
- Others
- Ophthalmology - R&D
- Androgen Tear
- Diquafosol
- Panzem
- Posurdex
- Sirna-027
- Triamcinolone
- Ophthalmology - Summary
- Growth Potential
- Limiting Factors
- Medical Dermatology - Products
- Tazorac/Zorac/Avage/Tazoral
- Sales
- Key Markets/Indications
- Further Development
- Licensees
- Sales Forecast
- Others
- Medical Dermatology - R&D
- Medical Dermatology - Summary
- Growth Potential
- Limiting Factors
- Other - R&D
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 2 - KEY AGREEMENTS
- Acadia Pharmaceuticals Inc
- 24th September 1997
- 18th November 1998
- 15th April 2003
- 8th January 2004
- 26th October 2004
- 3rd October 2005
- Boehringer Ingelheim
- EntreMed Inc
- ExonHit Therapeutics SA
- 26th February 2003
- 19th November 2003
- 13th December 2004
- 17th June 2005
- Inspire Pharmaceuticals Inc
- 27th June 2001
- 29th March 2002
- 8th December 2003
- ISTA Pharmaceuticals Inc
- March 2000
- 28th September 2004
- Kyorin Pharmaceutical Co Ltd
- 25th August 2000
- 26th May 2004
- Ligand Pharmaceuticals Inc
- Merz + Co GmbH & Co
- Miotech Inc
- Novartis
- 18th March 1993
- 19th April 2005
- Pfizer
- 8th October 1996
- 22nd July 1998
- 24th October 2002
- Sanwa Kagaku Kenkyusho Co Ltd
- Senju Pharmaceutical Co Ltd
- Valeant Pharmaceuticals International
- Other
APPENDIX 3 - INFRAST RUCTURE
- Manufacturing Facilities
- R&D Facilities
APPENDIX 4 - MAJOR PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
APPENDIX 5 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Geographical Area/Business Area
- Sales By Business Area
- Sales By Origin
- Long-Lived Assets By Geographical Area
- Recent Product Launches
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Major Launched Products
INDEX OF CHARTS
- Sales, Costs and Operating Income
- Capital Expenditure By Geographical Area/Business Area, 2005
- R&D Expenditure and Capital Expenditure
- Sales By Business Area
- Sales by Origin, 2005
- Sales of Major Product (2000A-2010E)
- Botox Sales (2000A-2010E)
- Alphagan Franchise Sales (2000A-2010E)
- Lumigan Sales (2000A-2010E)
- Restasis Sales (2000A-2010E)
- Tazorac Sales (2000A-2010E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
